{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:14:13Z","timestamp":1786119253959,"version":"build-2736575974"},"reference-count":73,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1097\/hco.0b013e32832c0b3d","type":"journal-article","created":{"date-parts":[[2009,6,8]],"date-time":"2009-06-08T03:18:51Z","timestamp":1244431131000},"page":"372-379","source":"Crossref","is-referenced-by-count":28,"title":["Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia"],"prefix":"10.1097","volume":"24","author":[{"given":"Anthony S","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-18-20210204","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive summary of the third report of The National Cholesterol Education Program (NCEP).","volume":"285","year":"2001","journal-title":"J Am Med Assoc"},{"key":"R2-18-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2007.08.024","article-title":"European guidelines on cardiovascular disease prevention in clinical practice: executive summary","volume":"194","author":"Graham","year":"2007","journal-title":"Atherosclerosis"},{"issue":"Suppl V","key":"R3-18-20210204","first-page":"v1","article-title":"Society, British Hypertension Society, Diabetes UK, HEART UK. Primary Care Cardiovascular Society, The Stroke Association: JBS 2: the Joint British Societies guidelines for prevention of cardiovascular disease in clinical practice.","volume":"91","year":"2005","journal-title":"Heart"},{"key":"R4-18-20210204","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"R5-18-20210204","doi-asserted-by":"crossref","first-page":"b92","DOI":"10.1136\/bmj.b92","article-title":"Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis","volume":"338","author":"Briel","year":"2009","journal-title":"Br Med J"},{"issue":"Suppl","key":"R6-18-20210204","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/0021-9150(94)90152-X","article-title":"Familial lipoprotein disorders and premature coronary artery disease","volume":"108","author":"Schaefer","year":"1994","journal-title":"Atherosclerosis"},{"key":"R7-18-20210204","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1742-1241.2007.01509.x","article-title":"HDL-c is a powerful lipid predictor of cardiovascular diseases","volume":"61","author":"Bruckert","year":"2007","journal-title":"Int J Clin Pract"},{"key":"R8-18-20210204","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1185\/030079905X74871","article-title":"High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients","volume":"21","author":"Bruckert","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R9-18-20210204","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1007\/s11883-000-0021-4","article-title":"Triglyceride, small, dense low-density lipoprotein, and the atherogenic lipoprotein phenotype","volume":"2","author":"Austin","year":"2000","journal-title":"Curr Atheroscler Rep"},{"key":"R10-18-20210204","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1373\/clinchem.2004.031757","article-title":"Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes","volume":"50","author":"Tan","year":"2004","journal-title":"Clin Chem"},{"key":"R11-18-20210204","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/j.1742-1241.2006.01122.x","article-title":"Low HDL-cholesterol: common and under-treated, but which drug to use?","volume":"60","author":"Wierzbicki","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R12-18-20210204","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0021-9150(03)00156-4","article-title":"Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives","volume":"171","author":"Chapman","year":"2003","journal-title":"Atherosclerosis"},{"key":"R13-18-20210204","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jacc.2008.09.049","article-title":"Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus","volume":"52","author":"Hiukka","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"R14-18-20210204","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1368-5031.2006.00882.x","article-title":"FIELDS of dreams, fields of tears: a perspective on the fibrate trials","volume":"60","author":"Wierzbicki","year":"2006","journal-title":"Int J Clin Pract"},{"key":"R15-18-20210204","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/BF00315136","article-title":"Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia","volume":"40","author":"Klosiewicz-Latoszek","year":"1991","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-18-20210204","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1185\/030079902125000516","article-title":"Effects of fibrates on serum metabolic parameters","volume":"18","author":"Elisaf","year":"2002","journal-title":"Curr Med Res Opin"},{"key":"R17-18-20210204","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jacc.2006.05.009","article-title":"The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study","volume":"48","author":"Muhlestein","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R18-18-20210204","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1042\/CS20060072","article-title":"Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome","volume":"111","author":"Watts","year":"2006","journal-title":"Clin Sci (Lond)"},{"key":"R19-18-20210204","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/j.bbalip.2007.02.003","article-title":"Safety issues and prospects for future generations of PPAR modulators","volume":"1771","author":"Rubenstrunk","year":"2007","journal-title":"Biochim Biophys Acta"},{"key":"R20-18-20210204","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1136\/bmj.4.5790.767","article-title":"Trial of clofibrate in the treatment of ischaemic heart disease. Five-year study by a group of physicians of the Newcastle upon Tyne region.","volume":"4","year":"1971","journal-title":"Br Med J"},{"key":"R21-18-20210204","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1136\/bmj.4.5790.775","article-title":"Ischaemic heart disease: a secondary prevention trial using clofibrate. Report by a research committee of the Scottish Society of Physicians.","volume":"4","year":"1971","journal-title":"Br Med J"},{"key":"R22-18-20210204","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease.","volume":"231","year":"1975","journal-title":"J Am Med Assoc"},{"key":"R23-18-20210204","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1136\/hrt.40.10.1069","article-title":"A co-operative trial in the primary prevention of ischaemic heart disease using clofibrate. Report from the Committee of Principal Investigators.","volume":"40","year":"1978","journal-title":"Br Heart J"},{"key":"R24-18-20210204","first-page":"600","article-title":"WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators.","volume":"2","year":"1984","journal-title":"Lancet"},{"key":"R25-18-20210204","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1463-1326.2007.00751.x","article-title":"Interpreting clinical trials of diabetic dyslipidaemia: new insights","volume":"11","author":"Wierzbicki","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"R26-18-20210204","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(96)91343-4","article-title":"Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients","volume":"347","author":"Ericsson","year":"1996","journal-title":"Lancet"},{"key":"R27-18-20210204","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1161\/01.CIR.96.7.2137","article-title":"Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group","volume":"96","author":"Frick","year":"1997","journal-title":"Circulation"},{"key":"R28-18-20210204","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"R29-18-20210204","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1365-2796.1994.tb01029.x","article-title":"The Helsinki Heart Study: an 8.5-year safety and mortality follow-up","volume":"235","author":"Huttunen","year":"1994","journal-title":"J Intern Med"},{"key":"R30-18-20210204","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1161\/01.CIR.92.7.1779","article-title":"Some coronary risk factors related to the insulin resistance syndrome and treatment with gemfibrozil. Experience from the Helsinki Heart Study","volume":"92","author":"Tenkanen","year":"1995","journal-title":"Circulation"},{"key":"R31-18-20210204","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"R32-18-20210204","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study.","volume":"102","year":"2000","journal-title":"Circulation"},{"key":"R33-18-20210204","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.amjcard.2008.08.033","article-title":"Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial)","volume":"103","author":"Goldenberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"R34-18-20210204","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/archinte.166.7.737","article-title":"Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate","volume":"166","author":"Tenenbaum","year":"2006","journal-title":"Arch Intern Med"},{"key":"R35-18-20210204","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1161\/01.CIR.0000126824.12785.B6","article-title":"Peroxisome proliferator-activated receptor ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease","volume":"109","author":"Tenenbaum","year":"2004","journal-title":"Circulation"},{"key":"R36-18-20210204","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1136\/bmj.325.7373.1139","article-title":"Bezafibrate in men with lower extremity arterial disease: randomised controlled trial","volume":"325","author":"Meade","year":"2002","journal-title":"Br Med J"},{"key":"R37-18-20210204","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"R38-18-20210204","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2337\/diacare.26.5.1513","article-title":"Insulin resistance and cardiovascular events with low HDL cholesterol: the Veterans Affairs HDL Intervention Trial (VA-HIT)","volume":"26","author":"Robins","year":"2003","journal-title":"Diabetes Care"},{"key":"R39-18-20210204","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"J Am Med Assoc"},{"key":"R40-18-20210204","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1161\/CIRCULATIONAHA.105.565135","article-title":"Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial","volume":"113","author":"Otvos","year":"2006","journal-title":"Circulation"},{"key":"R41-18-20210204","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1475-2840-3-9","article-title":"The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study [ISRCTN64783481].","volume":"3","year":"2004","journal-title":"Cardiovasc Diabetol"},{"key":"R42-18-20210204","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch Intern Med"},{"key":"R43-18-20210204","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/S0140-6736(00)04209-4","article-title":"Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.","volume":"357","year":"2001","journal-title":"Lancet"},{"key":"R44-18-20210204","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/1475-2840-4-13","article-title":"Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]","volume":"4","author":"Scott","year":"2005","journal-title":"Cardiovasc Diabetol"},{"key":"R45-18-20210204","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.2337\/dc05-2415","article-title":"Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN)","volume":"29","author":"Knopp","year":"2006","journal-title":"Diabetes Care"},{"key":"R46-18-20210204","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1046\/j.1464-5491.2002.00643.x","article-title":"Design of the Collaborative AtoRvastatin Diabetes Study (CARDS) in patients with type 2 diabetes","volume":"19","author":"Colhoun","year":"2002","journal-title":"Diabet Med"},{"key":"R47-18-20210204","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","article-title":"Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial","volume":"364","author":"Colhoun","year":"2004","journal-title":"Lancet"},{"key":"R48-18-20210204","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00043798-199604000-00014","article-title":"Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies","volume":"3","author":"Hokanson","year":"1996","journal-title":"J Cardiovasc Risk"},{"key":"R49-18-20210204","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"R50-18-20210204","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1001\/jama.294.19.2437","article-title":"High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial","volume":"294","author":"Pedersen","year":"2005","journal-title":"JAMA"},{"key":"R51-18-20210204","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"R52-18-20210204","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0140-6736(05)67504-6","article-title":"The PROactive study: some answers, many questions","volume":"366","author":"Yki-Jarvinen","year":"2005","journal-title":"Lancet"},{"key":"R53-18-20210204","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease: a pooled meta-analysis of long-term randomized placebo-controlled clinical trials","volume":"154","author":"Saha","year":"2007","journal-title":"Am Heart J"},{"key":"R54-18-20210204","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1185\/030079903125001668","article-title":"Statin-fibrate combination: therapy for hyperlipidemia: a review","volume":"19","author":"Wierzbicki","year":"2003","journal-title":"Curr Med Res Opin"},{"key":"R55-18-20210204","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.amjcard.2004.10.012","article-title":"Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)","volume":"95","author":"Grundy","year":"2005","journal-title":"Am J Cardiol"},{"key":"R56-18-20210204","doi-asserted-by":"crossref","first-page":"95","DOI":"10.7326\/0003-4819-142-2-200501180-00008","article-title":"A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events","volume":"142","author":"Whitney","year":"2005","journal-title":"Ann Intern Med"},{"key":"R57-18-20210204","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1007\/s00125-007-0751-8","article-title":"Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus","volume":"50","author":"Hiukka","year":"2007","journal-title":"Diabetologia"},{"key":"R58-18-20210204","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/eurheartj\/ehn347","article-title":"Concentration of apolipoprotein B is comparable with the apolipoprotein B\/apolipoprotein A-I ratio and better than routine clinical lipid measurements in predicting coronary heart disease mortality: findings from a multiethnic US population","volume":"30","author":"Sierra-Johnson","year":"2009","journal-title":"Eur Heart J"},{"key":"R59-18-20210204","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.amjcard.2007.11.046","article-title":"Relative atherogenicity and predictive value of nonhigh-density lipoprotein cholesterol for coronary heart disease","volume":"101","author":"Miller","year":"2008","journal-title":"Am J Cardiol"},{"key":"R60-18-20210204","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"R61-18-20210204","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1185\/030079905X26216","article-title":"Have we forgotten the pivotal role of high-density lipoprotein cholesterol in atherosclerosis prevention?","volume":"21","author":"Wierzbicki","year":"2005","journal-title":"Curr Med Res Opin"},{"key":"R62-18-20210204","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1001\/archinte.165.10.1154","article-title":"Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome","volume":"165","author":"Tenenbaum","year":"2005","journal-title":"Arch Intern Med"},{"key":"R63-18-20210204","doi-asserted-by":"crossref","first-page":"493","DOI":"10.2337\/dc08-1543","article-title":"Effects of fenofibrate treatment on cardiovascular disease risk in 9795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study","volume":"32","author":"Scott","year":"2009","journal-title":"Diabetes Care"},{"key":"R64-18-20210204","doi-asserted-by":"crossref","first-page":"3C","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"Davidson","year":"2007","journal-title":"Am J Cardiol"},{"key":"R65-18-20210204","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1053\/j.ajkd.2008.01.014","article-title":"Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people","volume":"51","author":"Ansquer","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"R66-18-20210204","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/S0140-6736(05)75415-5","article-title":"Implication of fibrate therapy for homocysteine","volume":"354","author":"Jonkers","year":"1999","journal-title":"Lancet"},{"key":"R67-18-20210204","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(07)61607-9","article-title":"Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial","volume":"370","author":"Keech","year":"2007","journal-title":"Lancet"},{"key":"R68-18-20210204","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/0026-0495(75)90102-X","article-title":"Diabetic retinopathy","volume":"24","author":"Kohner","year":"1975","journal-title":"Metabolism"},{"key":"R69-18-20210204","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.amjcard.2004.08.076","article-title":"Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin","volume":"95","author":"Jones","year":"2005","journal-title":"Am J Cardiol"},{"key":"R70-18-20210204","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1517\/13543784.17.10.1599","article-title":"Treatment of hyperlipidaemia with fenofibrate and related fibrates","volume":"17","author":"Filippatos","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"R71-18-20210204","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2008.10.025","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia","volume":"103","author":"Goldberg","year":"2009","journal-title":"Am J Cardiol"},{"key":"R72-18-20210204","doi-asserted-by":"crossref","first-page":"21i","DOI":"10.1016\/j.amjcard.2007.03.003","article-title":"Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods","volume":"99","author":"Buse","year":"2007","journal-title":"Am J Cardiol"},{"key":"R73-18-20210204","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1185\/030079905X43677","article-title":"Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel","volume":"21","author":"Shepherd","year":"2005","journal-title":"Curr Med Res Opin"}],"container-title":["Current Opinion in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/HCO.0b013e32832c0b3d","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:54:21Z","timestamp":1786038861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001573-200907000-00018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7]]},"references-count":73,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/hco.0b013e32832c0b3d","relation":{},"ISSN":["0268-4705"],"issn-type":[{"value":"0268-4705","type":"print"}],"subject":[],"published":{"date-parts":[[2009,7]]}}}